首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95 % SDS-PAGE |
| 种属 | Human |
| 靶点 | CCL17 |
| Uniprot No | Q92583 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-94aa |
| 氨基酸序列 | ARGTNVGREC CLEYFKGAIP LRKLKTWYQT SEDCSRDAIV FVTVQGRAIC SDPNNKRVKN AVKYLQSLER S |
| 预测分子量 | 8.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL17重组蛋白的3篇示例文献及其摘要概括(注：文献为示例性内容，实际引用需核实)：
1. **文献名称**：*CCL17 enhances Th2-cell chemotaxis in allergic asthma via CCR4 signaling*
**作者**：Yamashita U. et al.
**摘要**：研究重组CCL17蛋白对Th2细胞的趋化作用，证实其通过CCR4受体介导的信号通路加剧过敏性哮喘模型的炎症反应，为靶向治疗提供依据。
2. **文献名称**：*Recombinant CCL17 disrupts Treg/Th17 balance in autoimmune encephalomyelitis*
**作者**：Chen L. et al.
**摘要**：通过重组CCL17干预实验性自身免疫性脑脊髓炎(EAE)模型，发现其通过调控调节性T细胞(Treg)与Th17细胞的比例，影响疾病进展，揭示其在神经炎症中的双重作用。
3. **文献名称**：*Expression and functional analysis of CCL17 in tumor-associated macrophages*
**作者**：Müller G. et al.
**摘要**：报道重组CCL17蛋白在肿瘤微环境中的表达机制，证明其通过招募特定免疫细胞促进肿瘤免疫抑制，为癌症免疫治疗提供潜在靶点。
如需实际文献，建议在PubMed或Google Scholar中检索关键词“recombinant CCL17”“CCL17 function”等，并筛选涉及表达、功能或应用的研究。
CCL17 (C-C motif chemokine ligand 17), also known as thymus and activation-regulated chemokine (TARC), is a small secreted protein belonging to the CC chemokine family. It is primarily produced by dendritic cells, macrophages, and endothelial cells, playing a pivotal role in immune regulation by recruiting T helper 2 (Th2) cells, regulatory T cells (Tregs), and other CCR4-expressing leukocytes to inflammatory sites. CCL17 binds specifically to the CCR4 receptor, initiating signaling cascades that mediate chemotaxis and modulate immune responses in conditions such as allergic inflammation, autoimmune diseases, and cancer.
Recombinant CCL17 proteins are engineered using genetic recombination techniques to produce highly purified, biologically active forms of the chemokine. These proteins are typically expressed in mammalian cell systems (e.g., HEK293 or CHO cells) or prokaryotic systems (e.g., E. coli), with mammalian-derived versions often retaining post-translational modifications critical for receptor interaction. The recombinant form enables precise study of CCL17's functions in vitro and in vivo, including its role in Th2-polarized immune responses, tumor microenvironment modulation, and vascular inflammation. Researchers utilize it to investigate therapeutic targets for diseases like atopic dermatitis, asthma, and certain malignancies where CCL17/CCR4 signaling is dysregulated. Quality-controlled batches ensure consistency in experimental and preclinical studies, supporting drug discovery and mechanistic research.
×
